Login to Your Account

CSPC acquires stake in YZY through $55M deal; gains bispecific antibodies

By David Ho
Staff Writer

Friday, January 12, 2018

HONG KONG – CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, has made plans to acquire a 39.56 percent stake in Wuhan YZY Biopharma Co. Ltd. in a deal worth up to ¥356 million (US$54.6 million).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription